GlassScriptPhysician profile
Petra J Thomas
NPI 1518957661
$4,002.77
in general payments reported to CMS, 2019-2025
32 companies · $1,685 in 2025
The $1,685 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.77 · 2020: $84.51 · 2021: $155 · 2022: $240 · 2023: $549 · 2024: $1,270 · 2025: $1,685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,129 · Education: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,128.51 |
| Education | $375.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,248.65 | 2021-2025 | Tezspire, Breztri, Fasenra |
| Glaxosmithkline, LLC. | $600.95 | 2021-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Regeneron Healthcare Solutions, INC. | $551.82 | 2020-2025 | Dupixent |
| Genzyme Corporation | $201.92 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $166.94 | 2024-2025 | |
| Insmed, INC. | $140.01 | 2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $109.26 | 2023-2024 | Yupelri |
| Amgen INC. | $101.90 | 2022-2025 | Tezspire |
| United Therapeutics Corporation | $86.49 | 2023-2024 | Tyvaso |
| Harmony Biosciences LLC | $79.34 | 2024-2025 | |
| Lilly USA, LLC | $69.20 | 2020-2025 | Zepbound |
| Biogen, INC. | $61.23 | 2021-2022 | |
| Inspire Medical Systems, INC. | $60.64 | 2025 | Inspire |
| Viatris Specialty LLC | $58.06 | 2025 | Yupelri |
| Jazz Pharmaceuticals INC. | $50.50 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $38.22 | 2022 | |
| Genentech USA, INC. | $33.66 | 2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $33.15 | 2023 | Glassia |
| Verona Pharma, INC. | $32.61 | 2025 | Ohtuvayre |
| Electromed, INC. | $30.02 | 2025 | Smartvest |
| Mallinckrodt Hospital Products INC. | $25.86 | 2023 | Acthar |
| Integra Lifesciences Corporation | $23.80 | 2022 | |
| Pulmonx Corporation | $22.66 | 2023 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Grifols USA, LLC | $22.40 | 2024 | Prolastin-C Liquid |
| Baxter Healthcare | $21.49 | 2025 | Hillrom - Monarch Airway Clearance System |
| Pfizer INC. | $21.30 | 2024 | |
| Corcept Therapeutics | $19.80 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.77 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.60 | 2023 | |
| Avadel Cns Pharmaceuticals, LLC | $18.44 | 2025 | Lumryz |
| Biohaven Pharmaceutical Holding Company LTD. | $17.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.10 | 2025 | Ofev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Petra Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.